1 Leiomyosarcoma Drug Market Overview 1.1 Product Overview and Scope of Leiomyosarcoma Drug 1.2 Leiomyosarcoma Drug Segment by Type 1.2.1 Global Leiomyosarcoma Drug Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 AL-3818 1.2.3 BGB-290 1.2.4 C-21 1.2.5 Others 1.3 Leiomyosarcoma Drug Segment by Application 1.3.1 Leiomyosarcoma Drug Sales Comparison by Application: (2021-2027) 1.3.2 Clinic 1.3.3 Hospital 1.3.4 Others 1.4 Global Leiomyosarcoma Drug Market Size Estimates and Forecasts 1.4.1 Global Leiomyosarcoma Drug Revenue 2016-2027 1.4.2 Global Leiomyosarcoma Drug Sales 2016-2027 1.4.3 Leiomyosarcoma Drug Market Size by Region: 2016 Versus 2021 Versus 2027 2 Leiomyosarcoma Drug Market Competition by Manufacturers 2.1 Global Leiomyosarcoma Drug Sales Market Share by Manufacturers (2016-2021) 2.2 Global Leiomyosarcoma Drug Revenue Market Share by Manufacturers (2016-2021) 2.3 Global Leiomyosarcoma Drug Average Price by Manufacturers (2016-2021) 2.4 Manufacturers Leiomyosarcoma Drug Manufacturing Sites, Area Served, Product Type 2.5 Leiomyosarcoma Drug Market Competitive Situation and Trends 2.5.1 Leiomyosarcoma Drug Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Leiomyosarcoma Drug Players Market Share by Revenue 2.5.3 Global Leiomyosarcoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Leiomyosarcoma Drug Retrospective Market Scenario by Region 3.1 Global Leiomyosarcoma Drug Retrospective Market Scenario in Revenue by Region: 2016-2021 3.2 Global Leiomyosarcoma Drug Retrospective Market Scenario in Sales by Region: 2016-2021 3.3 North America Leiomyosarcoma Drug Market Facts & Figures by Country 3.3.1 North America Leiomyosarcoma Drug Sales by Country 3.3.2 North America Leiomyosarcoma Drug Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Leiomyosarcoma Drug Market Facts & Figures by Country 3.4.1 Europe Leiomyosarcoma Drug Sales by Country 3.4.2 Europe Leiomyosarcoma Drug Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Leiomyosarcoma Drug Market Facts & Figures by Region 3.5.1 Asia Pacific Leiomyosarcoma Drug Sales by Region 3.5.2 Asia Pacific Leiomyosarcoma Drug Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Leiomyosarcoma Drug Market Facts & Figures by Country 3.6.1 Latin America Leiomyosarcoma Drug Sales by Country 3.6.2 Latin America Leiomyosarcoma Drug Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Leiomyosarcoma Drug Market Facts & Figures by Country 3.7.1 Middle East and Africa Leiomyosarcoma Drug Sales by Country 3.7.2 Middle East and Africa Leiomyosarcoma Drug Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Leiomyosarcoma Drug Historic Market Analysis by Type 4.1 Global Leiomyosarcoma Drug Sales Market Share by Type (2016-2021) 4.2 Global Leiomyosarcoma Drug Revenue Market Share by Type (2016-2021) 4.3 Global Leiomyosarcoma Drug Price by Type (2016-2021) 5 Global Leiomyosarcoma Drug Historic Market Analysis by Application 5.1 Global Leiomyosarcoma Drug Sales Market Share by Application (2016-2021) 5.2 Global Leiomyosarcoma Drug Revenue Market Share by Application (2016-2021) 5.3 Global Leiomyosarcoma Drug Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Advenchen Laboratories, LLC 6.1.1 Advenchen Laboratories, LLC Corporation Information 6.1.2 Advenchen Laboratories, LLC Description and Business Overview 6.1.3 Advenchen Laboratories, LLC Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Advenchen Laboratories, LLC Product Portfolio 6.1.5 Advenchen Laboratories, LLC Recent Developments/Updates 6.2 BeiGene, Ltd. 6.2.1 BeiGene, Ltd. Corporation Information 6.2.2 BeiGene, Ltd. Description and Business Overview 6.2.3 BeiGene, Ltd. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.2.4 BeiGene, Ltd. Product Portfolio 6.2.5 BeiGene, Ltd. Recent Developments/Updates 6.3 Cell Medica Limited 6.3.1 Cell Medica Limited Corporation Information 6.3.2 Cell Medica Limited Description and Business Overview 6.3.3 Cell Medica Limited Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.3.4 Cell Medica Limited Product Portfolio 6.3.5 Cell Medica Limited Recent Developments/Updates 6.4 Karyopharm Therapeutics, Inc. 6.4.1 Karyopharm Therapeutics, Inc. Corporation Information 6.4.2 Karyopharm Therapeutics, Inc. Description and Business Overview 6.4.3 Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Karyopharm Therapeutics, Inc. Product Portfolio 6.4.5 Karyopharm Therapeutics, Inc. Recent Developments/Updates 6.5 Merck & Co., Inc. 6.5.1 Merck & Co., Inc. Corporation Information 6.5.2 Merck & Co., Inc. Description and Business Overview 6.5.3 Merck & Co., Inc. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.5.4 Merck & Co., Inc. Product Portfolio 6.5.5 Merck & Co., Inc. Recent Developments/Updates 6.6 Mirati Therapeutics Inc. 6.6.1 Mirati Therapeutics Inc. Corporation Information 6.6.2 Mirati Therapeutics Inc. Description and Business Overview 6.6.3 Mirati Therapeutics Inc. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.6.4 Mirati Therapeutics Inc. Product Portfolio 6.6.5 Mirati Therapeutics Inc. Recent Developments/Updates 6.7 Novartis AG 6.6.1 Novartis AG Corporation Information 6.6.2 Novartis AG Description and Business Overview 6.6.3 Novartis AG Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Novartis AG Product Portfolio 6.7.5 Novartis AG Recent Developments/Updates 6.8 Vicore Pharma AB 6.8.1 Vicore Pharma AB Corporation Information 6.8.2 Vicore Pharma AB Description and Business Overview 6.8.3 Vicore Pharma AB Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.8.4 Vicore Pharma AB Product Portfolio 6.8.5 Vicore Pharma AB Recent Developments/Updates 7 Leiomyosarcoma Drug Manufacturing Cost Analysis 7.1 Leiomyosarcoma Drug Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Leiomyosarcoma Drug 7.4 Leiomyosarcoma Drug Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Leiomyosarcoma Drug Distributors List 8.3 Leiomyosarcoma Drug Customers 9 Leiomyosarcoma Drug Market Dynamics 9.1 Leiomyosarcoma Drug Industry Trends 9.2 Leiomyosarcoma Drug Growth Drivers 9.3 Leiomyosarcoma Drug Market Challenges 9.4 Leiomyosarcoma Drug Market Restraints 10 Global Market Forecast 10.1 Leiomyosarcoma Drug Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Leiomyosarcoma Drug by Type (2022-2027) 10.1.2 Global Forecasted Revenue of Leiomyosarcoma Drug by Type (2022-2027) 10.2 Leiomyosarcoma Drug Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Leiomyosarcoma Drug by Application (2022-2027) 10.2.2 Global Forecasted Revenue of Leiomyosarcoma Drug by Application (2022-2027) 10.3 Leiomyosarcoma Drug Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Leiomyosarcoma Drug by Region (2022-2027) 10.3.2 Global Forecasted Revenue of Leiomyosarcoma Drug by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Leiomyosarcoma Drug Sales (K Pcs) Growth Rate Comparison by Type (2021-2027) Table 2. Global Leiomyosarcoma Drug Sales (K Pcs) Comparison by Application (2021-2027) Table 3. Global Leiomyosarcoma Drug Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Leiomyosarcoma Drug Covered in This Study Table 5. Global Leiomyosarcoma Drug Sales (K Pcs) of Key Manufacturers (2016-2021) Table 6. Global Leiomyosarcoma Drug Sales Share by Manufacturers (2016-2021) Table 7. Global Leiomyosarcoma Drug Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Leiomyosarcoma Drug Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Leiomyosarcoma Drug Average Price (USD/Pcs) of Key Manufacturers (2016-2021) Table 10. Manufacturers Leiomyosarcoma Drug Manufacturing Sites and Area Served Table 11. Manufacturers Leiomyosarcoma Drug Product Type Table 12. Global Leiomyosarcoma Drug Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Leiomyosarcoma Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Leiomyosarcoma Drug as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Leiomyosarcoma Drug Sales by Region (2016-2021) & (K Pcs) Table 16. Global Leiomyosarcoma Drug Sales Market Share by Region (2016-2021) Table 17. Global Leiomyosarcoma Drug Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Leiomyosarcoma Drug Sales by Country (2016-2021) & (K Pcs) Table 19. North America Leiomyosarcoma Drug Sales Market Share by Country (2016-2021) Table 20. North America Leiomyosarcoma Drug Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Leiomyosarcoma Drug Revenue Market Share by Country (2016-2021) Table 22. Europe Leiomyosarcoma Drug Sales by Country (2016-2021) & (K Pcs) Table 23. Europe Leiomyosarcoma Drug Sales Market Share by Country (2016-2021) Table 24. Europe Leiomyosarcoma Drug Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Leiomyosarcoma Drug Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Leiomyosarcoma Drug Sales by Region (2016-2021) & (K Pcs) Table 27. Asia Pacific Leiomyosarcoma Drug Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Leiomyosarcoma Drug Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Leiomyosarcoma Drug Revenue Market Share by Region (2016-2021) Table 30. Latin America Leiomyosarcoma Drug Sales by Country (2016-2021) & (K Pcs) Table 31. Latin America Leiomyosarcoma Drug Sales Market Share by Country (2016-2021) Table 32. Latin America Leiomyosarcoma Drug Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Leiomyosarcoma Drug Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Leiomyosarcoma Drug Sales by Country (2016-2021) & (K Pcs) Table 35. Middle East and Africa Leiomyosarcoma Drug Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Leiomyosarcoma Drug Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Leiomyosarcoma Drug Revenue Market Share by Country (2016-2021) Table 38. Global Leiomyosarcoma Drug Sales (K Pcs) by Type (2016-2021) Table 39. Global Leiomyosarcoma Drug Sales Market Share by Type (2016-2021) Table 40. Global Leiomyosarcoma Drug Revenue (Million US$) by Type (2016-2021) Table 41. Global Leiomyosarcoma Drug Revenue Share by Type (2016-2021) Table 42. Global Leiomyosarcoma Drug Price (USD/Pcs) by Type (2016-2021) Table 43. Global Leiomyosarcoma Drug Sales (K Pcs) by Application (2016-2021) Table 44. Global Leiomyosarcoma Drug Sales Market Share by Application (2016-2021) Table 45. Global Leiomyosarcoma Drug Revenue (Million US$) by Application (2016-2021) Table 46. Global Leiomyosarcoma Drug Revenue Share by Application (2016-2021) Table 47. Global Leiomyosarcoma Drug Price (USD/Pcs) by Application (2016-2021) Table 48. Advenchen Laboratories, LLC Corporation Information Table 49. Advenchen Laboratories, LLC Description and Business Overview Table 50. Advenchen Laboratories, LLC Leiomyosarcoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 51. Advenchen Laboratories, LLC Leiomyosarcoma Drug Product Table 52. Advenchen Laboratories, LLC Recent Developments/Updates Table 53. BeiGene, Ltd. Corporation Information Table 54. BeiGene, Ltd. Description and Business Overview Table 55. BeiGene, Ltd. Leiomyosarcoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 56. BeiGene, Ltd. Leiomyosarcoma Drug Product Table 57. BeiGene, Ltd. Recent Developments/Updates Table 58. Cell Medica Limited Corporation Information Table 59. Cell Medica Limited Description and Business Overview Table 60. Cell Medica Limited Leiomyosarcoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 61. Cell Medica Limited Leiomyosarcoma Drug Product Table 62. Cell Medica Limited Recent Developments/Updates Table 63. Karyopharm Therapeutics, Inc. Corporation Information Table 64. Karyopharm Therapeutics, Inc. Description and Business Overview Table 65. Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 66. Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Product Table 67. Karyopharm Therapeutics, Inc. Recent Developments/Updates Table 68. Merck & Co., Inc. Corporation Information Table 69. Merck & Co., Inc. Description and Business Overview Table 70. Merck & Co., Inc. Leiomyosarcoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 71. Merck & Co., Inc. Leiomyosarcoma Drug Product Table 72. Merck & Co., Inc. Recent Developments/Updates Table 73. Mirati Therapeutics Inc. Corporation Information Table 74. Mirati Therapeutics Inc. Description and Business Overview Table 75. Mirati Therapeutics Inc. Leiomyosarcoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 76. Mirati Therapeutics Inc. Leiomyosarcoma Drug Product Table 77. Mirati Therapeutics Inc. Recent Developments/Updates Table 78. Novartis AG Corporation Information Table 79. Novartis AG Description and Business Overview Table 80. Novartis AG Leiomyosarcoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 81. Novartis AG Leiomyosarcoma Drug Product Table 82. Novartis AG Recent Developments/Updates Table 83. Vicore Pharma AB Corporation Information Table 84. Vicore Pharma AB Description and Business Overview Table 85. Vicore Pharma AB Leiomyosarcoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 86. Vicore Pharma AB Leiomyosarcoma Drug Product Table 87. Vicore Pharma AB Recent Developments/Updates Table 88. Production Base and Market Concentration Rate of Raw Material Table 89. Key Suppliers of Raw Materials Table 90. Leiomyosarcoma Drug Distributors List Table 91. Leiomyosarcoma Drug Customers List Table 92. Leiomyosarcoma Drug Market Trends Table 93. Leiomyosarcoma Drug Growth Drivers Table 94. Leiomyosarcoma Drug Market Restraints Table 95. Global Leiomyosarcoma Drug Sales Forecast by Type (2022-2027) & (K Pcs) Table 96. Global Leiomyosarcoma Drug Sales Market Share Forecast by Type (2022-2027) Table 97. Global Leiomyosarcoma Drug Revenue Forecast by Type (2022-2027) & (US$ Million) Table 98. Global Leiomyosarcoma Drug Revenue Market Share Forecast by Type (2022-2027) Table 99. Global Leiomyosarcoma Drug Sales Forecast by Application (2022-2027) & (K Pcs) Table 100. Global Leiomyosarcoma Drug Sales Market Share Forecast by Application (2022-2027) Table 101. Global Leiomyosarcoma Drug Revenue Forecast by Application (2022-2027) & (US$ Million) Table 102. Global Leiomyosarcoma Drug Revenue Market Share Forecast by Application (2022-2027) Table 103. Global Leiomyosarcoma Drug Sales Forecast by Region (2022-2027) & (K Pcs) Table 104. Global Leiomyosarcoma Drug Sales Market Share Forecast by Region (2022-2027) Table 105. Global Leiomyosarcoma Drug Revenue Forecast by Region (2022-2027) & (US$ Million) Table 106. Global Leiomyosarcoma Drug Revenue Market Share Forecast by Region (2022-2027) Table 107. Research Programs/Design for This Report Table 108. Key Data Information from Secondary Sources Table 109. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Leiomyosarcoma Drug Figure 2. Global Leiomyosarcoma Drug Market Share by Type in 2020 & 2027 Figure 3. AL-3818 Product Picture Figure 4. BGB-290 Product Picture Figure 5. C-21 Product Picture Figure 6. Others Product Picture Figure 7. Global Leiomyosarcoma Drug Market Share by Application in 2020 & 2027 Figure 8. Clinic Figure 9. Hospital Figure 10. Others Figure 11. Global Leiomyosarcoma Drug Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 12. Global Leiomyosarcoma Drug Market Size 2016-2027 (US$ Million) Figure 13. Global Leiomyosarcoma Drug Sales 2016-2027 (K Pcs) Figure 14. Global Leiomyosarcoma Drug Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 15. Leiomyosarcoma Drug Sales Share by Manufacturers in 2020 Figure 16. Global Leiomyosarcoma Drug Revenue Share by Manufacturers in 2020 Figure 17. The Global 5 and 10 Largest Leiomyosarcoma Drug Players: Market Share by Revenue in 2020 Figure 18. Leiomyosarcoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 19. Global Leiomyosarcoma Drug Sales Market Share by Region (2016-2021) Figure 20. Global Leiomyosarcoma Drug Sales Market Share by Region in 2020 Figure 21. Global Leiomyosarcoma Drug Revenue Market Share by Region (2016-2021) Figure 22. Global Leiomyosarcoma Drug Revenue Market Share by Region in 2020 Figure 23. U.S. Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 24. Canada Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 25. Germany Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. France Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. U.K. Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. Italy Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. Russia Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. China Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. Japan Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. South Korea Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. India Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. Australia Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. Taiwan Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Indonesia Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Thailand Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Malaysia Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Philippines Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Vietnam Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Mexico Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Brazil Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Argentina Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Turkey Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. Saudi Arabia Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. U.A.E Leiomyosarcoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 47. Sales Market Share of Leiomyosarcoma Drug by Type (2016-2021) Figure 48. Sales Market Share of Leiomyosarcoma Drug by Application (2016-2021) Figure 49. Sales Market Share of Leiomyosarcoma Drug by Application in 2020 Figure 50. Revenue Share of Leiomyosarcoma Drug by Application (2016-2021) Figure 51. Revenue Share of Leiomyosarcoma Drug by Application in 2020 Figure 52. Manufacturing Cost Structure of Leiomyosarcoma Drug Figure 53. Manufacturing Process Analysis of Leiomyosarcoma Drug Figure 54. Leiomyosarcoma Drug Industrial Chain Analysis Figure 55. Channels of Distribution Figure 56. Distributors Profiles Figure 57. Bottom-up and Top-down Approaches for This Report Figure 58. Data Triangulation Figure 59. Key Executives Interviewed

Advenchen Laboratories, LLC BeiGene, Ltd. Cell Medica Limited Karyopharm Therapeutics, Inc. Merck & Co., Inc. Mirati Therapeutics Inc. Novartis AG Vicore Pharma AB